Auriculotherapy
Procedure3 sessions of auriculotherapy at one month intervals.
NCT Number: NCT03036761
The aim of the study is to show that auriculotherapy decreases the number of days with painful episodes of migraine and headache after 3 months of treatment
Looking for future studies?
Notify Me18 month–80 year
Female
Interventional
Not applicable
Cabinet Médical, Maisons-Alfort, France
Prospective, multicenter, controlled and randomized study.
At the inclusion:
Patients are randomized in 2 groups (distribution 2/3 AUR+, 1/3 AUR-):
After 3 months, a visit of Algology is carried out :
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Non inclusion Criteria:
Exclusion criteria
3 sessions of auriculotherapy at one month intervals.
Time frame: 3 months
Evaluated with the patient's migraine/headache/treatment diary of the last 3 months after inclusion.
One day with painful episodes of migraines and non-migraines headaches is a day when:
Time frame: 3 months
Evaluated with the patient's migraine/headache/treatment diay of the last 3 months after inclusion.
One day with painful episodes of migraines is a day when:
Time frame: 3 months
Evaluated with the patient's migraine/headache/treatment diary of the last 3 months after inclusion.
One day with painful episodes of non-migraines headaches is a day when:
Time frame: 3 months
The intensity of the pain episodes is evaluated by the patient on a numerical scale of 1 to 3 (1 = low, 2 = moderate, 3 = intense) which is in the patient's migraine/headache/treatment diary of the 3 months after inclusion.
The outcome is evaluated by the calculation of the sum of the pain intensities of migraines and non-migraine headaches .
Time frame: 3 months
Evaluated with the patient's migraine/headache/treatment diary of the last 3 months after inclusion.
The sum of antalgic use (triptan and non-triptan):
Time frame: 3 months
Calculation of the MIDAS score during the inclusion visit and 3 months after the inclusion visit.
Time frame: 3 months
The presence or absence of adverse events attributed to the treatment of auriculotherapy by the patient.
Hopital Foch
Other
Acronym: Migauric
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06891118
Brain Diseases, Central Nervous System Diseases
Ankara, Cankaya, Turkey (Türkiye)
View Trial DetailsNCT03472092
Brain Diseases, Central Nervous System Diseases
Cincinnati, Ohio, United States
View Trial DetailsNCT05853900
Brain Diseases, Central Nervous System Diseases
New York, United States
View Trial DetailsNCT04736654
Brain Diseases, Central Nervous System Diseases
Ankara, None Selected, Turkey (Türkiye)
View Trial Details